Cancer Clinical Trials in Southwest Washington

Meningiomas
A071401 Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Any solid tumor with brain mets
A071701 Genomically-Guided Treatment Trial in Brain Metastases (from any solid tumor-Central screening for alteration in CDK pathway, P13K/AKT/mTOR pathway, and NTRK/ROS1 translocation.)

Recurrent GBM
A071702 A Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatically Hypermutated Recurrent Glioblastoma

HER 2+
A011801 The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer ): COMPASSHER2 Residual Disease (RD), A Double Blinded Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib

Triple Neg
NRG-BR003 Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel with or Without Carboplatin in Treating Patients with Triple-Negative Breast Cancer

HER 2+ Met.
NRG-BR004 A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First Line HER2-Positive Metastatic Breast Cancer

HER 2+
EA1181 (CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer )

HER 2 neg-Met.
S1703 Serum Tumor marker Directed Disease Monitoring in patients with Hormone Receptor positive HER2 Negative Metastatic Breast Cancer

Inflammatory
S1706 A Phase II Randomized Trial of Olaparib (NSC-747856) Administered concurrently with RT vs. RT alone for Inflammatory Breast Cancer (Available only at PeaceHealth Southwest)

HER 2 Neg with brain mets
S2007 A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC#820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases

SURVIVOR
URCC-18007 Randomized Placebo Controlled Trial of Bupropion for Cancer Related Fatigue in stage I-III breast cancer survivors

Stage III colon
A021502 Combination Chemotherapy with or Without Atezolizumab in Treating Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair

Neuroendocrine
A021602 Cabozantinib S-malate in Treating Patients with Neuroendocrine Tumors previously Treated with Everolimus that are locally advanced, metastatic or cannot be removed by surgery

Metastatic colorectal
A021703 Randomized Double Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)

Prevent peripheral neuropathy
A221805 Duloxetine to prevent Oxaliplatin-induced peripheral neuropathy : A Randomized, Double blind placebo controlled phase II study

Esophageal
EA2174 A Phase II/III study of Peri-operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma

Metastatic Anal
EA2176 A Phase III Study of Immune Checkpoint inhibition with chemotherapy in treatment naive metastatic anal cancer patients

Anal
EA2182 A Randomized Phase II study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)

Metastatic pancreatic 70 and older
EA2186 A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients (70 and older) with Treatment Naïve Metastatic Pancreatic Cancer (GIANT)

Resected pancreatic
EA2192 APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Adjuvant Chemotherapy in Patients with Resected pancreatic Cancer and a Pathogenic BRCA1, BRCA2, or PALB2 Mutation

Rectal
EA2201 A Phase II Study of Neoadjuvant Nivolumab plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma

IIA colon
GI005 Phase II/III study of Circulating tumor DNA as a predictive Biomarker in adjuvant chemotherapy in stage IIA colon cancer (COBRA)

Polyp prevention
S0820 Adenoma and Second Primary Prevention Trial

Refractory small bowel
S1922 Randomized Phase II Selection Study of Ramucirumab and Paclitaxel vs. FOLFIRI in refractory small bowel adenocarcinoma

Metastatic pancreatic
S2001 Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib alone as maintenance Therapy in Metastatic Pancreatic Cancer patients with Germline BRCA1 or BRCA2 Mutations.

Pancreatic Neuroendocrine
S2104 Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High Risk Pancreatic Neuroendocrine Tumors

Rare GU
A031702 A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers

Metastatic renal cell
A031704 PD-Inhibitor (Nivolumab) and Ipilimumab followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal cell cancer

Metastatic urothelial
A031901 Duration of Immune checkpoint Therapy in Locally advanced or Metastatic Urothelial Carcinoma: A Randomized Phase III Non-Inferiority Trial

Metastatic prostate
A031902 CASPAR, A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-resistant Prostate Cancer

Prostate radiosurgery registry
NCT01226004 Multi-Institutional Registry for Prostate Cancer Radiosurgery  (Available only at PeaceHealth Southwest)

Recurrent endometrial or ovarian
NRG-GY014 A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma

Stage II-IV ovarian or peritoneal
GY019 A Randomized Phase III, Two-arm trial of Paclitaxel/Carboplatin/Maintenance Letrozole versus Letrozole monotherapy in Patients with Stage II-IV, Primary Low grade Serous Carcinoma of the Ovary or Peritoneum

Recurrent ovarian, peritoneal or fallopian
GY023 A Randomized Phase II Trial of Triplet Therapy (a PD-L1 Inhibitor Durvalumab in combination with Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab and Cediranib or Standard of Care Chemotherapy in Women with Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary peritoneal or Fallopian cancer who have received prior Bevacizumab

Squamous Head/Neck
EA3132 Phase II Randomized Trial of Adjuvant Radiotherapy with or without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)

HPV oropharyngeal
EA3161 A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in patients with Locally Advanced, Intermediate Risk HPV Positive Oropharyngeal Cancer

Squamous Head/Neck
RTOG 1216 Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High Risk Squamous Cell Cancer of the Head and Neck   (Available only at PeaceHealth St. John, Longview)

Resected IB-IIIA NSCLC
A151216 Adjuvant Genetic Testing in Screening Patients with Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery ( The ALCHEMIST Screening Trial )

ALCHEMIST substudy resected NSCLC
A081801 Integration of Immunotherapy into adjuvant therapy for resected NSCLC: ALCHEMIST Chemo-IO

ALCHEMIST substudy resected NSCLC
E4512 Crizotinib in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

Met. Or recurrent NSCLC
LUNGMAP A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study) (substudies: S1900A, S1900E)

Recurrent or stage IV NSCLC
A171901 Older NSCLC patients (>/= 70 years of age ) Treated with First-Line MK-3475 (Pembrolizumab) +/- Chemotherapy (Oncologists/patients choice)

Stage IV non-squamous NSCLC
EA5163 INSIGNA:A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non ‐ Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature‐driven Analysis

Unresectable III, NSCLC
EA5181 Randomized Phase III trial of MEDI4736 (Durvalumab) as concurrent and consolidative therapy or consolidative therapy alone for unresectable stage 3 NSCLC

Metastatic NSCLC EGFR
EA5182 Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

NSCLC-previously tx
EA5191 A Randomized Phase II Trial of Cabozantinib and Cabozantinib plus Nivolumab Vs. Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC

SCLC extensive stage
SWOG S1929 Phase II Randomized Study of Maintenance Atezolizumab Vs. Atezolizumab in Combination with Talazoparib in patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)

I-IIA NSCLC
SWOG S1914 A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC 783608) + SBRT vs. SBRT alone in High Risk, Early Stage NSCLC (Available only at PeaceHealth Southwest)

>70 yr old CLL
A041702 A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

CML
S1712 Ruxolitinib Phosphate and Dasatinib or Nilotinib in Treating patients with Chronic Myeloid Leukemia

CLL/SLL
S1925 Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly diagnosed Asymptomatic High-Risk patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia/Small Lymphocytic Lymphoma : EVOLVE CLL/SLL study

Untreated mantle cell
EA4181 A Randomized 3-Arm Phase II study comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib, and 3.) Bendamustine, Rituximab and Acalabrutinib in patients < 70 years old with untreated Mantle Cell Lymphoma

Hodgkin lymphoma
S1826 A Phase III, randomized study of Nivolumab plus AVD or Brentuximab Vedotin plus AVD in patients with newly diagnosed advanced stage classical Hodgkin Lymphoma

Waldenstrom’s/lymphoplasmacytic lymphoma
S2005 A Phase II Randomized Study of Ibrutinib and Rituximab with or without Venetoxclax in Previously Untreated Waldenstrom’s Macroglobulinemia/Lymphoplasmacytic Lymphoma

Stage III-IV melanoma
S1801 A Phase II Randomized Study of Adjuvant Vs. Neoadjuvant MK-3475 (Pembrolizumab) for clinically Detectable Stage III-IV High Risk Melanoma

Melanoma with brain mets
S2000 A Randomized Phase II Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF V6000 Mutant Melanoma with brain Metastases

Merkel Cell
EA6174 STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma with Pembrolizumab, A Phase III trial

Smoldering myeloma
EAA173 Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma

Immune related AE registry
A151804 Establishment of a National Biorepository to Advance Studies of Immune Related Adverse Events

Registry of clinical trials participation
DCP001 Use of a Clinical Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)

Rare tumors-check cohort
S1609 DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors

Financial hardship for metastatic solid tumor and hematologic cancers
S1912CD A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Interverntion (CREDIT)

Observation of immune checkpoint inhibitor toxicities
S2013 Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study